Relief Effort Progress Highlighted at the Clinton Global
Initiative Annual Meeting in New York, September 26-29, 2015
IRVINE, Calif.--(BUSINESS WIRE)--Sep. 27, 2015--
Masimo
(NASDAQ: MASI) announced progress today at the 2015 Clinton Global
Initiative Annual Meeting towards its commitment to donate $5 million in
Signal Extraction Technology® Pulse Oximeters and Pulse CO-Oximeters®
and other medical equipment to Jordanian hospitals to help improve
patient care for Syrian and Iraqi refugees, as well as Jordanian
citizens. A progress report video highlighting the Masimo relief effort
was featured at the Plenary Session called Investing in Prevention
and Resilient Health Systems. The first shipment of equipment is
already in use at Al-Bashir hospital in Amman. The rest of the equipment
will arrive at the Ministry of Health Office in Jordan shortly. Masimo
also committed to provide ongoing training and technical support to the
clinicians in Jordan.
The wars in Syria and Iraq are one of the largest ongoing humanitarian
crises in the world, with over an estimated million people seeking
refuge now living within Jordan’s borders, more than 600,000 of whom are
registered with the United Nations High Commissioner for Refugees
(UNHCR). Managing healthcare is a critical requirement of stability
during crises and, while new hospitals are being built near refugee
camps, the vast majority of refugees reside in existing communities,
heightening the demand for health services throughout Jordan. The
significant burden of providing healthcare services both for routine and
emergency needs is worsening daily.
“The people of Jordan have opened their hearts and country to help their
neighbors in need,” said Joe Kiani, Founder and CEO of Masimo. “The
situation in Syria keeps getting worse. The people of Jordan are our
heroes – taking in the Palestinian refugees, the Iraqi refugees, then
the Egyptian refugees, and now the large influx of Syrian refugees. We
knew our plan for aid needed to be long-term. We not only donated the
much needed oximeters, other medical equipment, and supplies but we also
committed to train and provide continued technical support for the
Jordanian clinicians that assist in the front line care of the people of
Jordan. The need is great and it is too overwhelming for just a few
countries to shoulder. As global citizens, we all need to get involved
and help the people of Syria and those trying to save them.”
Masimo’s commitment to Jordan is one of several ongoing CGI commitments,
and was made at a roundtable meeting convened by CGI in 2014, at which
President Clinton and his Majesty King Abdullah Il ibn Al Hussein of
Jordan met with Masimo’s Joe Kiani, among others, to discuss the
humanitarian crisis.
The measurements provided by pulse oximeters are often referred to as
the “fifth vital sign.” In a report published by the Jordanian
government, they are identified as one of the most needed pieces of
hospital equipment. Pulse oximeters allow a health worker to monitor a
person’s oxygen levels. Confirming oxygen levels in the blood is
critical as it helps identify those in need of care, those who are
deteriorating, and those who are not. Pulse oximeters are widely used
from health clinics to emergency departments, from surgery and the
intensive care unit to the general floor. Over 100 million patients are
monitored with Masimo SET® pulse oximeters around the world and in more
than 100 comparative studies Masimo SET® outperformed other
technologies. Researchers have found that Masimo SET® in combination
with changes in clinical practice led to a reduction in retinopathy of
prematurity (ROP) in preterm babies in the neonatal intensive care unit
(NICU)¹ and an increase of 31% in the detection of newborns with
critical congenital heart disease (CCHD) when used as a part of the CCHD
screening protocol.2 Researchers found improved outcomes3
following the installation of continuous patient monitoring with Masimo
SET® on post-surgical patients, including that zero patients suffered
brain damage or died over a five-year period.4 A recent study
with a Masimo Pulse CO-Oximeter® (SpHb and PVI) also showed that 30-day
mortality after surgeries dropped by 25%.5
1. Castillo A, Deulofeut R, Critz A, Sola A. Prevention of retinopathy
of prematurity in preterm infants through changes in clinical practice
and SpO2 technology. Acta Paediatr. 2011 Feb;100(2):188-92.
2. de-Wahl Granelli A, Wennergren M, Sandberg K, Mellander M, Bejlum C,
Inganäs L, Eriksson M, Segerdahl N, Agren A, Ekman-Joelsson BM,
Sunnegårdh J, Verdicchio M, Ostman-Smith I. Impact of pulse oximetry
screening on the detection of duct dependent congenital heart disease: a
Swedish prospective screening study in 39,821 newborns. BMJ. 2009
Jan 8;338:a3037.
3. Taenzer AH, Pyke JB, McGrath SP, Blike GT. Impact of pulse oximetry
surveillance on rescue events and intensive care unit transfers: a
before-and-after concurrence study. Anesthesiology. 2010
Feb;112(2):282-7.
4. Taenzer et al. The Dartmouth Experience. APSF Newsletter.
Spring-Summer 2012. Volume 27, No. 1, 1-28.
5. Ponsonnard S, Yonnet S, Marin B, Cros J, Ben Miled S, Nathan N.
“Continuous Hb and plethysmography variability index (PVI) monitoring is
associated to a decreased mortality at the scale of a whole hospital.”
Proceedings of the European Society of Anaesthesiology’s Euroanaesthesia
2015 Annual Congress, May 30-June 2, Berlin, Germany, 16AP3-2, Room A1 –
Poster Abstract Presentation Session, e-Board 8.
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through-Motion and Low Perfusion™ pulse oximetry,
which has been shown in multiple studies to significantly reduce false
alarms and accurately monitor for true alarms. The benefits of Masimo
SET® have been proven in more than 100 independent and objective studies
and it is estimated to be used on more than 100 million patients in
leading hospitals and other healthcare settings around the world. In
2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition
to SpO2, pulse rate, and perfusion index (PI). Additional information
about Masimo and its products may be found at www.masimo.com.
About the Clinton Global Initiative
Established in 2005 by President Bill Clinton, the Clinton Global
Initiative (CGI), an initiative of the Clinton Foundation, convenes
global leaders to create and implement solutions to the world's most
pressing challenges. CGI Annual Meetings have brought together 190
sitting and former heads of state, more than 20 Nobel Prize laureates,
and hundreds of leading CEOs, heads of foundations and NGOs, major
philanthropists, and members of the media. To date, members of the CGI
community have made more than 3,200 Commitments to Action, which have
improved the lives of over 430 million people in more than 180 countries.
In addition to the Annual Meeting, CGI convenes CGI America, a meeting
focused on collaborative solutions to economic recovery in the United
States; and CGI University (CGI U), which brings together undergraduate
and graduate students to address pressing challenges in their community
or around the world. This year, CGI also convened CGI Middle East &
Africa, which brought together leaders across sectors to take action on
pressing social, economic, and environmental challenges.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including: total hemoglobin (SpHb®) contributes to
positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions with comparable accuracy and unique advantages,
including: immediate and continuous results that enable earlier
treatment without causing invasive trauma in all patients and in every
clinical situation; as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities
and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks
or registered trademarks of Masimo Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150927005068/en/
Source: Masimo
Masimo Corporation
Irene Paigah, 858-616-8689
irenep@masimo.com